Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy
GI AEs following the use of targeted antibody-drug conjugates can involve various gastrointestinal systems. In our patient cohort who received BV or PV, GI AEs were typically low grade and managed with supportive care or corticosteroids. Nonetheless, some patients experienced high-grade AEs or symptom recurrence and stopped BV/PV therapy. Future studies may provide clarification and guide clinical practice.
Authors
- Ugochi Ebinama (ORCID: https://orcid.org/0000-0002-5750-2787)
- Andrew Kuang (ORCID: https://orcid.org/0000-0002-3431-6885)
- Paolo Strati
- Malek Shatila (ORCID: https://orcid.org/0000-0001-8503-7811)
- Hao Chi Zhang (ORCID: https://orcid.org/0000-0003-0330-0167)
- Sidra Naz (ORCID: https://orcid.org/0009-0007-7233-7824)
- Swaminathan P. Iyer
- Anusha S. Thomas
- Nitish Mittal
- Mehnaz A. Shafi
- Jay S. Shah
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- University of Pennsylvania Health System (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17588359261417635
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00